Melanoma, mutacijski znak raka, lahko spremeni zdravljenje
Raziskovalci so na konferenci Evropskega združenja za medicinsko onkologijo v Madridu leta 2026 predstavili rezultate študije faze 3 INTerpath- 001, ki so poudarili novo personalizirano terapevtsko cepivo za melanom. Eksperimentalno zdravljenje, znano kot intismeran autogene, uporablja tehnologijo mRNA za ciljanje specifičnih neoantigenov tumorja, ki so identificirani s pomočjo edinstvenega mutacijskega podpisa pacienta. Zdravilo, ki sta ga skupaj razvila podjetja Merck Sharp Dohme (Msd) in Moderna, so preizkusili v kombinaciji z obstoječim zdravilom pembrolizumab pri bolnikih z melanomom v stadijih IIB- IV, ki so bili popolnoma odstranjeni s kirurškim posegom. Podatki so pokazali, da je bilo tveganje za ponovni pojav ali smrt pri zdravljenju z intismeranom v kombinaciji z pembrolizumabom po medianu obdobja spremljanja 24, 6 meseca zmanjšano za 42 odstotkov v primerjavi z uporabo samega pembrolizumaba. Poleg tega je kombinirani pristop zmanjšal tveganje za oddaljene metastaze ali smrt na splošno za 38 odstotkov, pri čemer so analize občutljivosti pokazale 58- odstotno zmanjšanje tveganja za ponovitve, ki se je začelo šest mesecev po začetku zdravljenja. Te ugotovitve so bile sprejete za objavo v The New England Journal of Medicine in kažejo na potencialni prehod v smeri personalizirane imunske terapije za zgodnje do m
A personalized therapeutic vaccine based on messenger RNA technology has demonstrated efficacy against melanoma, reducing the risk of disease recurrence by 42 percent over two years when added to standard immunotherapy. These findings from the phase three clinical trial INTerpath-001 were presented at the Congress of the European Society for Medical Oncology in Madrid. The results mark the first time a fully customized therapeutic vaccine has shown benefit in a phase three study. The data are scheduled for publication in the New England Journal of Medicine this November. The trial enrolled 1,137 patients with high-risk melanoma who had undergone complete surgical removal of their tumors. Participants were treated across 157 centers worldwide. Italy contributed the highest number of patients among all countries involved in the study. The treatment regimen combined the vaccine, known as intismeran autogene, with pembrolizumab, an immune checkpoint inhibitor developed by Merck Sharp & Dohme. The vaccine was developed jointly by MSD and Moderna. Patients received nine doses of the vaccine over a period of one year. After a median follow-up of 24.6 months, the combination therapy reduced the risk of recurrence or death by 42 percent compared to pembrolizumab alone. It also lowered the risk of distant metastasis or death by 38 percent. An analysis conducted after the initial six-month immunization period showed even greater benefits. From month six onward, adding the vaccine to pembrolizumab reduced the risk of recurrence or death by 58 percent and halved the risk of distant metastasis or death. During the first six months of treatment, the efficacy of the combination was comparable to that of pembrolizumab alone. The vaccine is designed specifically for each patient’s unique tumor profile. Researchers sequence the DNA of the removed tumor tissue to identify mutations. They then synthesize mRNA in a laboratory to encode up to 34 neoantigens, which are mutated proteins exclusive to that individual’s cancer cells. Once injected, these instructions direct the patient’s cells to produce the neoantigens. This process presents a detailed biological signature of the tumor to the immune system, enabling it to recognize and destroy residual cancer cells circulating in the body. The goal is to prevent recurrence by strengthening the immune response against specific targets left behind after surgery. Michele Del Vecchio, head of medical oncology for melanomas at the National Cancer Institute in Milan, stated that INTerpath-001 is the first and only phase three study demonstrating superior results with the combination of mRNA vaccine and immunotherapy compared to standard care. He noted that the new combination showed good tolerability without an increase in side effects relative to immunotherapy alone. The Italian center led by Del Vecchio recruited 82 patients, making it the site with the largest enrollment globally. Paola Queirolo, coordinator of the melanoma network at the Metropolitan Hospital of Genoa, explained that the vaccine is therapeutic rather than preventive. It is administered after surgery to further boost the immune system against the specific molecular characteristics of the patient’s tumor. Georgina Long, the principal investigator of the study and director of the Melanoma Institute in Australia, described the results as transformative. She said the findings support a radically new approach to adjuvant treatment that adapts therapy to the unique mutational signature of each patient’s tumor. For decades, oncological treatments have been largely defined by the anatomical origin of the cancer. Long indicated that while these results apply to stage IIB through IV completely resected melanoma, they provide valuable insights as clinical research continues in other tumor types and settings. In Italy, approximately 13,000 new cases of melanoma are diagnosed annually. About 5,000 of these patients would be candidates for this type of therapy. The preparation of the personalized vaccine requires a complex organizational effort involving oncologists, surgeons, pathologists, molecular biologists, and pharmacists. The process involves analyzing adequate tumor samples, selecting neoantigens, and producing the final product, which takes approximately six weeks. The vaccine is not yet available for general use. Regulatory agencies including the US Food and Drug Administration, the European Medicines Agency, and the Italian Medicines Agency are currently reviewing the application. In the interim, authorities will consider activating special access programs for patients. While the cost of the personalized vaccine remains high, efforts are underway to reduce prices to ensure accessibility and sustainability. Research teams are already applying the same principle to develop mRNA vaccines for other cancers, including lung, pancreatic, and genitourinary tumors. The success of this trial provides a foundation for expanding this personalized approach beyond melanoma.
V kliničnem preskušanju faze 3 je popolnoma prilagojeno terapevtsko cepivo z mRNK pokazalo učinkovitost proti melanomom, s čimer je zmanjšalo tveganje za ponovitve bolezni za 42 odstotkov, ko se je v dveh letih dodalo standardni imunoterapiji. Rezultati študije INTerpath- 001 so bili predstavljeni na kongresu Evropskega združenja za medicinsko onkologijo in naj bi bili objavljeni v New England Journal of Medicine. V preskušanju je bilo vključenih 1137 bolnikov z visokim tveganjem v 157 svetovnih centrih, pri čemer je Italija prispevala največje število vključenih udeležencev. Cepivo, znano kot mRNA-4157, je izdelano po meri na podlagi edinstvenih mutacij DNK posameznega pacienta, da bi spodbudilo imunski odziv proti preostalim rakotvornim celicam. Italijanski onkologi so ugotovili, da bi lahko približno 5000 bolnikov letno koristilo od te terapije, ki je pokazala dobro prenašanje brez povečanih stranskih učinkov v primerjavi z immunoterapijo.
Ocena pristranskosti (Sredina): Članek poroča o rezultatih medicinskih raziskav v zvezi z novim zdravljenjem raka. V njem so navedeni znanstveni podatki, rezultati kliničnih preskušanj in mnenja onkologov. Z njim ni povezano nobene politične polemike, partizanskega oblikovanja ali ideološke razprave, zaradi česar je nepolitičen.
Zakaj dejstva (95): The article accurately reflects the core findings of the INTerpath-001 study presented at ESMO, including the 42% reduction in recurrence risk and the involvement of 1,137 patients. It correctly identifies the mechanism (mRNA-based personalized vaccine targeting neoantigens) and the combination ther
Zakaj objektivnost (95): The tone is informative and professional, typical of a wire service report. It presents the scientific breakthrough neutrally without excessive hype or emotional language, focusing on the clinical data and implications.
Il GiornaleStrankarsko povezanSredinaDejstva: uradni vir/dokument ni zaznanObjektivnost 95
Klinično preskušanje faze 3 z imenom INTerpath- 001 je pokazalo, da personalizirano terapevtsko cepivo z mRNA znatno zmanjša tveganje za ponovitve raka pri bolnikih z melanomom z visokim tveganjem. V študijo je bilo vključenih 1. 137 bolnikov, ki so bili podvrženi radikalni operaciji in so bili zdravljeni z cepivom v kombinaciji z pembrolizumabom ali samo z pembrolizumabom. Rezultati, ki so bili predstavljeni na konferenci Evropskega združenja za medicinsko onkologijo v Madridu, so pokazali, da je v primerjavi s samo standardno imunoterapijo povečanje tveganja za ponovni pojav s cepivom zmanjšalo za 42 odstotkov in tveganje za oddaljene metastaze za 38 odstotkov. Zdravljenje je bilo dobro prenašano in v skupini, ki je prejemala kombinacijo zdravil, niso opazili znatnega povečanja neželenih učinkov. To je prvič, da je individualizirana neoantigenska terapija pokazala korist v preskušanju faze 3, kar bi lahko spremenilo standard oskrbe s tem stanjem.
Ocena pristranskosti (Sredina): Članek poroča o rezultatih medicinskih raziskav v zvezi z novim zdravljenjem raka. Citira posebne klinične podatke in strokovne komentarje italijanskega onkologa, vendar se ne ukvarja s politično razpravo, zagovarjanjem politike ali partizansko oblikovanjem. Vsebina je strogo znanstvena in informativna.
Zakaj dejstva: uradni vir/dokument ni zaznan
Zakaj objektivnost (95): Neutral and balanced reporting. Uses direct quotes to convey enthusiasm rather than injecting editorial opinion. Clearly distinguishes between the new therapy and current standards, providing context without bias.
Il GiornaleStrankarsko povezanSredinaDejstva: uradni vir/dokument ni zaznanObjektivnost 90
Raziskovalci so na konferenci Evropskega združenja za medicinsko onkologijo v Madridu leta 2026 predstavili rezultate študije faze 3 INTerpath- 001, ki so poudarili novo personalizirano terapevtsko cepivo za melanom. Eksperimentalno zdravljenje, znano kot intismeran autogene, uporablja tehnologijo mRNA za ciljanje specifičnih neoantigenov tumorja, ki so identificirani s pomočjo edinstvenega mutacijskega podpisa pacienta. Zdravilo, ki sta ga skupaj razvila podjetja Merck Sharp Dohme (Msd) in Moderna, so preizkusili v kombinaciji z obstoječim zdravilom pembrolizumab pri bolnikih z melanomom v stadijih IIB- IV, ki so bili popolnoma odstranjeni s kirurškim posegom. Podatki so pokazali, da je bilo tveganje za ponovni pojav ali smrt pri zdravljenju z intismeranom v kombinaciji z pembrolizumabom po medianu obdobja spremljanja 24, 6 meseca zmanjšano za 42 odstotkov v primerjavi z uporabo samega pembrolizumaba. Poleg tega je kombinirani pristop zmanjšal tveganje za oddaljene metastaze ali smrt na splošno za 38 odstotkov, pri čemer so analize občutljivosti pokazale 58- odstotno zmanjšanje tveganja za ponovitve, ki se je začelo šest mesecev po začetku zdravljenja. Te ugotovitve so bile sprejete za objavo v The New England Journal of Medicine in kažejo na potencialni prehod v smeri personalizirane imunske terapije za zgodnje do m
Ocena pristranskosti (Sredina): Članek poroča o rezultatih medicinskih raziskav in kliničnih preskušanj v zvezi z zdravljenjem raka. Osredotoča se na znanstvene podatke, farmacevtski razvoj in strokovne komentarje o merilih učinkovitosti. V tem predmetu ni politične polemike, partizanskega oblikovanja ali ideološke razprave.
Zakaj dejstva: uradni vir/dokument ni zaznan
Zakaj objektivnost (90): While largely objective, the headline uses slightly promotional language ('potrà cambiare la cura'), though this is common in medical journalism covering major breakthroughs. The body text remains balanced and cites specific data points clearly.
Kako je poročala vsaka stran
Isti dogodek, razvrščen po političnem nagibu medijev, ki so o njem poročali.
progresivno
sredina
konservativno
★
Kako je poročala vsaka stran
Podprite neodvisne novice z zavedanjem pristranskosti in odklenite družbeni utrip, glasovanje skupnosti in vse druge funkcije za podpornike.
Italy
